This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Subscribe To Our Newsletter & Stay Updated
